Skip to content

lymphedema and laser therapy in women with breast cancer

Treatment of Postmastectomy Lymphedema with Laser Therapy; Double Blind Placebo Control Randomized Study

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12610000027011
Enrollment
50
Registered
2010-01-11
Start date
2010-01-22
Completion date
Unknown
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This prospective, double-blind, placebo, controlled randomized, study was conducted to evaluate the effects of low level laser therapy (LLLT) in the management of breast cancer related lymphedema.

Interventions

Fifty-eight women with postmastectomy lymphedema were enrolled in a double-blind, placebo controlled trial. Patients were randomly assigned to active laser (n=28) and placebo (n=26) groups and received irradiation with Ga–As laser over the axillary and arm areas, for 20 mniutes , 3 times a week for 12 weeks. The total energy applied at each point was 300mJoules over 17 points (5.1 Joules in total), giving a dosage of 1.5 Joules/cm2 in the active group. The placebo group received placebo therapy

Fifty-eight women with postmastectomy lymphedema were enrolled in a double-blind, placebo controlled trial. Patients were randomly assigned to active laser (n=28) and placebo (n=26) groups and received irradiation with Ga–As laser over the axillary and arm areas, for 20 mniutes , 3 times a week for 12 weeks. The total energy applied at each point was 300mJoules over 17 points (5.1 Joules in total), giving a dosage of 1.5 Joules/cm2 in the active group. The placebo group received placebo therapy in which the laser had been disabled without affecting its apparent function. Limb circumference, shoulder mobility, and grip strength were measured before treatment and at 4, 8, and 12 weeks, laser therapy applied only on the affected limb not bilateral.

Sponsors

Mohammed Taher Ahmed Omar
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
45 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

women with breast cancer related lymphedema (swelling of more than 2cm and less than 8cm of excess limb circumference at each point compared to controlled non operative limb

Exclusion criteria

Patients who had a current metastases , continuing radiotherapy, cellulites, venous thrombosis, chronic inflammatory diseases, history of sever trauma, photosensitivity or who were using any medication that affect body fluid and electrolyte balance were excluded. .Patients with bilateral lymphedema were also excluded because the contralateral normal limb was needed to predicate percentage of lymphedema.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026